🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Regeneron Pharmaceuticals, Inc. REGN NDXSPXR3KPHARMA

Healthcare · Biotechnology · United States
https://www.regeneron.com
Company Profile ↓
$827.72
+48.21% 1Y
Mkt Cap$83.71B
P/E20.50
P/B2.48
Div. Yield0.49%
52W High$852.03
52W Low$552.68
Book Value$316.11
EPS (TTM)$40.38

Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 16.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 29.2% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 20.5, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 27.9%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.09.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $14.34B (+1.0% YoY); net profit $4.50B.
  • Trailing 12 Months Year-on-year growth — revenue +16.7%, earnings -4.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 29.2%, profit CAGR 16.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:29.18%
1 Year:16.70%

Compounded Profit Growth

5 Years:16.32%
1 Year:-4.50%

Stock Price Performance

1 Year:+48.21%
6 Months:+9.22%
3 Months:+30.41%
1 Month:+7.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 92% of range
$552.68 $852.03
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross2d ago
  • RSI (14)60.54 · Neutral
Price Performance
1M+7.33%
3M+30.41%
6M+9.22%
1Y+48.21%
Valuation vs Sector

P/E of 20.50 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Excellent profit margin of 27.9%.
  • Compounding revenue at 29.2% over 5 years.
  • Profit CAGR of 16.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
20.50
Industry PE
25.17
Forward P/E
13.77
PEG Ratio
1.31
Book Value
$316.11
Price to Book
2.48
P/S
5.20
EV/EBITDA
15.53
Dividend Yield
0.49%

Growth (CAGR)

Revenue 5Y
29.18%
Profit 5Y
16.32%
Revenue (YoY)
16.70%
Earnings (YoY)
-4.50%

Profitability & Returns

ROCE
10.23%
ROE
14.04%
ROA
6.53%
Profit Margin
27.87%
Op Margin
33.11%
Gross Margin
44.46%
EPS (Latest Qtr)
$12.23
EPS (TTM)
$40.38

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
2.63
Current Ratio
3.33
Debt
$2.71B
Total Assets
$41.73B
Current Assets
$18.21B
Working Capital
$13.65B

Ownership

Promoter Holding
2.08%
Chg in Prom Hold
0.00%
FII / Inst Holding
93.51%
Chg in FII Hold
0.06%

Financial Snapshot

Enterprise Value
$83.71B
Total Revenue (TTM)
$15.53B
EBITDA
$4.70B
Free Cash Flow
$3.07B
Operating Cash Flow
$4.68B
Shares Outstanding
101.14M
Gross Margin
44.46%
Payout Ratio
9.01%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 REGN Regeneron Pharmaceuticals, Inc. NDXSPXR3KPHARMA 827.72 20.50 $83.71B 0.49% 10.23% 14.04% 29.18% 16.32%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -----1.32B1.47B1.50B1.58B1.51B1.61B1.66B1.93B1.37B1.58B1.74B1.86B1.83B1.95B2.29B2.42B2.53B5.14B3.45B2.97B2.86B2.94B3.16B3.16B3.36B3.15B3.55B--3.03B3.68B3.75B3.88B3.61B4.29B
Cost of Revenue ----------------------------------464.30M530.20M521.60M584.60M669.40M-
Gross Profit ----------------------------------2.56B3.15B3.23B3.30B2.94B-
Operating Expenses ----------------------------------1.97B2.07B2.12B2.40B2.19B-
Operating Income -329.31M291.63M362.80M-430.54M550.31M559.93M-567.20M622.20M626.90M-480.00M315.60M738.50M-700.10M656.40M1.05B-1.11B3.35B1.85B1.26B1.11B1.22B946.70M1.02B1.11B751.40M1.07B--591.70M1.08B1.11B898.60M744.80M1.29B
EBITDA ----------------------------------1.04B1.66B1.92B1.20B967.30M-
Interest Expense ----------------------------------8.70M3.60M19.30M12.20M12.90M-
Pretax Income ----------------------------------905.00M1.52B1.76B1.04B831.20M-
Tax Provision ----------------------------------96.30M127.10M303.30M199.10M104.00M-
Net Income 154.99M181.38M196.22M264.80M253.12M248.90M387.70M388.30M173.50M478.00M551.40M594.70M820.40M461.10M193.10M669.60M792.00M624.60M897.30M842.10M1.15B1.12B3.10B1.63B973.50M852.10M1.32B817.80M968.40M1.01B722.00M1.43B--808.70M1.39B1.46B844.60M727.20M1.30B
Diluted EPS 1.341.591.692.272.192.163.343.321.504.164.825.177.153.991.685.866.935.437.617.3910.2410.0927.9714.338.617.4711.667.178.508.896.2712.41--7.2712.8113.627.866.7512.23
R&D Expense -470.11M559.93M543.05M-507.44M509.98M529.75M-498.60M529.30M557.00M-486.10M885.50M526.00M-583.90M722.00M684.60M-742.90M714.20M665.40M843.80M794.30M911.30M1.10B1.09B1.08B1.25B1.20B1.27B-1.33B1.42B1.48B-1.54B1.63B

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 238.46M379.27M459.07M445.82M1.38B2.10B2.82B4.10B4.86B5.87B5.15B6.56B8.50B-12.17B13.12B14.20B14.34B
Cost of Revenue --------------1.56B1.82B1.97B2.10B
Gross Profit --------------10.61B11.30B12.23B12.24B
Operating Expenses --------------5.87B7.25B8.24B8.54B
Operating Income -86.25M-74.10M-97.47M-205.16M457.71M743.05M823.92M1.25B1.33B2.08B2.53B2.21B3.58B-4.74B4.05B3.99B3.70B
EBITDA --------------5.26B4.69B5.32B5.82B
Interest Expense --------------59.40M73.00M55.20M43.80M
Pretax Income --------------4.86B4.20B4.78B5.23B
Tax Provision --------------520.40M245.70M367.30M725.80M
Net Income -79.13M-67.83M-104.47M-221.76M750.27M413.74M338.13M636.06M895.50M1.20B2.44B2.12B3.51B-4.34B3.95B4.41B4.50B
Diluted EPS ---1.26-2.456.753.722.985.527.7010.3421.2918.4630.52-38.2234.7738.3441.48
R&D Expense 274.90M398.76M489.25M529.51M625.55M859.95M1.27B1.62B2.05B2.08B1.47B2.45B2.65B2.86B3.59B4.44B5.13B5.85B

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --741.20M1.09B1.32B2.08B2.95B3.84B5.61B6.97B8.76B11.73B14.81B17.16B-29.21B33.08B37.76B40.56B
Current Assets ---------------15.88B19.48B18.66B18.02B
Cash & Equivalents 498.93M247.80M207.07M112.57M483.61M230.28M535.61M648.72M809.10M535.20M812.70M1.47B1.62B2.19B-3.11B2.73B2.49B3.12B
Inventory ---------------2.40B2.58B3.09B3.20B
Receivables ---------------5.33B5.67B6.21B5.74B
Total Liabilities --344.44M561.62M837.85M835.11M998.94M1.29B1.95B2.52B2.62B2.98B3.72B6.14B-6.55B7.11B8.41B9.30B
Current Liabilities --93.58M109.06M148.27M163.55M298.83M654.66M811.16M1.24B1.14B1.44B2.10B2.70B-3.14B3.42B3.94B4.37B
Long Term Debt ------------01.98B-1.98B1.98B1.98B1.99B
Total Debt ---------------2.70B2.70B2.70B2.71B
Total Equity 459.35M421.51M396.76M527.82M485.73M1.26B1.96B2.55B3.65B4.45B6.14B8.76B11.09B11.03B-22.66B25.97B29.35B31.26B
Shares Outstanding ---------------132.20M134.92M137.82M139.42M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -89.09M-69.94M99.22M-141.68M-74.61M588.60M752.43M1.33B1.49B1.31B2.20B2.43B2.62B-5.01B4.59B4.42B4.98B
Investing Cash Flow 30.82M-2.15M-437.03M128.47M-81.07M-355.45M-420.78M-907.60M-1.05B-1.01B-1.46B-2.03B-70.60M--3.78B-3.19B-2.47B-629.10M
Financing Cash Flow -192.86M31.36M243.31M384.25M-97.65M72.19M-218.55M-262.80M-700.50M-24.40M-77.10M-252.10M-1.97B--1.01B-1.79B-2.20B-3.72B
Capital Expenditure ---------------1.62B-926.40M-881.60M-1.21B
Free Cash Flow --------------3.40B3.67B3.54B3.77B
Net Change in Cash --------------221.30M-381.20M-248.10M634.40M
Share Buybacks --------004.40M275.90M5.85B1.65B2.08B2.23B2.60B3.44B
Dividends Paid ---------------00370.30M

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------87.2%86.2%86.1%85.4%
Operating Margin % -36.2%-19.5%-21.2%-46.0%33.2%35.3%29.2%30.5%27.4%35.4%49.3%33.7%42.1%-38.9%30.9%28.1%25.8%
Net Margin % -33.2%-17.9%-22.8%-49.7%54.4%19.7%12.0%15.5%18.4%20.4%47.5%32.3%41.3%-35.6%30.1%31.1%31.4%
ROE % -18.8%-17.1%-19.8%-45.7%59.7%21.1%13.3%17.4%20.1%19.5%27.9%19.1%31.9%-19.1%15.2%15.0%14.4%
ROCE % --11.4%-9.9%-17.5%23.9%28.0%25.9%26.1%23.2%27.3%24.6%17.4%24.7%-18.2%13.6%11.8%10.2%

Shareholding Pattern

Insiders
2.08%
Institutions
93.51%
Public Float
95.50%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.01% 9.11M $7.24B
2 Vanguard Capital Management LLC 6.56% 6.63M $5.27B
3 Dodge & Cox Inc. 4.82% 4.87M $3.87B
4 State Street Corporation 4.78% 4.83M $3.84B
5 Invesco Ltd. 3.90% 3.94M $3.13B
6 JPMORGAN CHASE & CO 3.73% 3.77M $3.00B
7 Vanguard Portfolio Management LLC 3.14% 3.18M $2.52B
8 Franklin Resources, Inc. 2.74% 2.77M $2.20B
9 Geode Capital Management, LLC 2.60% 2.63M $2.09B
10 Nuveen, LLC 2.00% 2.02M $1.60B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for REGN

Yahoo Finance Fri, 04 Sep 2026

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

They could both outperform the market over the medium term, but one appears to have a clear edge.

Yahoo Finance Wed, 02 Sep 2026

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Path…

Yahoo Finance Wed, 02 Sep 2026

Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?

Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.

Yahoo Finance Sun, 30 Aug 2026

Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View

Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reductio…

Yahoo Finance Sat, 29 Aug 2026

Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP

Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debili…

Yahoo Finance hu, 27 Aug 2026

Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?

The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, te…

REGN — Frequently Asked Questions

What is the current share price of Regeneron Pharmaceuticals, Inc. (REGN)?

As of 2026-09-07 16:24 PDT, Regeneron Pharmaceuticals, Inc. (REGN) trades at $827.72 on NasdaqGS. Its 52-week range is $552.68 to $852.03.

What is the market capitalisation of REGN?

Regeneron Pharmaceuticals, Inc. (REGN) has a market capitalisation of $83.71B on NasdaqGS.

What is the P/E ratio of REGN?

REGN trades at a trailing price-to-earnings (P/E) ratio of 20.50. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.48.

Does REGN pay a dividend?

Regeneron Pharmaceuticals, Inc. (REGN) currently offers a dividend yield of 0.49%.

What is the return on equity (ROE) of REGN?

REGN has a return on equity (ROE) of 14.04%. Its return on capital employed (ROCE) is 10.23%.

Is REGN a good stock to buy?

This page provides a data-driven analysis of Regeneron Pharmaceuticals, Inc. (REGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space